what are glp-1 drugs made from The revolution: UAB researchers discovering about how these work Frontiers | Exploring the multifaceted
Description
Introduction Significant reductions in cardiovascular events, all-cause mortality, and the advancement of kidney disease are demonstrated by important studies such as FLOW
Individual results may vary
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor
Glucagon-like peptide-1 (GLP-1) receptor is widely distributed in the digestive system, cardiovascular system, adipose tissue and central nervous system
There can be side effects and risks: GLP-1 drugs affect multiple systems (pancreas, kidney, GI tract) and are not without cost or health implications
It does not imply endorsement, ranking, or medical recommendation
